Ikarovec
Ikarovec is a UK clinical-stage biotechnology company developing a proprietary bicistronic AAV8 gene therapy platform that delivers two therapeutic proteins in a single injection to treat vision-threatening retinal diseases, principally geographic atrophy, wet AMD, intermediate AMD, and diabetic macular edema.
- Company typePrivate
- Founded2020
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ikarovec does
Ikarovec Limited is a UK private biotechnology company founded in 2020 as a spin-out from Quethera (acquired by Astellas Pharmaceuticals in 2018), headquartered at Innovation Centre, Norwich Research Park, Norfolk. The company is developing a proprietary bicistronic AAV8 gene therapy platform that uses a linker technology to co-express two synergistic therapeutic proteins in a single vector, enabling dual-pathway intervention in retinal disease. Its lead product IKAR-001 (formerly IKC159V) combines pigment epithelium-derived factor (PEDF) for neuroprotection with soluble CD46 (sCD46) for complement modulation to treat geographic atrophy (GA), delivered as a one-time subretinal injection. The pipeline extends to IKAR-002 (anti-VEGF and anti-CTGF for wet AMD), IKAR-003 (dual-pathway therapy for intermediate AMD using VectorBuilder's intravitreal capsid), and an undisclosed candidate for diabetic macular edema.
Ikarovec operates pre-commercially with no approved or marketed products and is funded by LifeArc Ventures, Parkwalk Advisors, and UKI2S (managed by Future Planet Capital). As of October 2025 the company had £8M in cumulative seed funding and was conducting a $46M Series A targeted to close in Q1 2026 (25% verbally committed), with manufacturing underway at a GMP CDMO partner and an Australian clinical trial application advancing toward Phase I/IIa initiation. The intended go-to-market is specialty ophthalmology clinics and hospital-based retina centers globally, with one-time treatment administration replacing frequent anti-VEGF injections; no pricing has been disclosed.
The leadership team is built around commercialising ocular gene therapy: President and CEO Thomas Ciulla (appointed May 2025) previously directed Luxturna medical strategy at Spark Therapeutics and led Izervay to FDA approval at Iveric Bio; CSO Katie Binley brings 30 years of gene therapy experience from Oxford BioMedica; Scientific Founder Peter Widdowson co-founded Quethera; and Chair David Guyer founded Iveric Bio and Eyetech Pharmaceuticals. In January 2026 the company signed an exclusive worldwide option agreement with VectorBuilder for a novel intravitreal AAV capsid (potential deal value above $1bn) to support IKAR-003.
Ikarovec firmographics
Firmographics- Name
- Ikarovec
- Legal name
- Ikarovec Limited
- Website
- https://ikarovec.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ikarovec is a UK clinical-stage biotechnology company developing a proprietary bicistronic AAV8 gene therapy platform that delivers two therapeutic proteins in a single injection to treat vision-threatening retinal diseases, principally geographic atrophy, wet AMD, intermediate AMD, and diabetic macular edema.
- Ownership category
- akta.pro rank
Ikarovec industry classification
Industry- Product category
- Ophthalmic Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Gene Therapies (HLAAACAG)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Ikarovec is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Ikarovec business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Gene Therapy Product Sales: Pre-revenue clinical stage biotech developing gene therapies for ophthalmic diseases. Once approved, products would be commercialized through specialty ophthalmology channels with a one-time injection treatment model.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Ikarovec product offering
Product offeringCore offering
Ikarovec is a clinical-stage biotechnology company developing a pipeline of bi-functional (bicistronic) gene therapies that use AAV8 vectors to deliver genetic instructions for two synergistic therapeutic proteins in a single injection. Lead product IKAR-001 targets geographic atrophy via PEDF neuroprotection and sCD46 complement modulation; IKAR-002 addresses wet AMD via anti-VEGF and anti-CTGF; IKAR-003 targets intermediate AMD using VectorBuilder's intravitreal capsid.
Product overview
Ikarovec is a near-clinical stage biotechnology company pioneering a proprietary bicistronic (bi-functional) gene therapy platform for vision-threatening retinal diseases. The platform utilizes AAV8 vectors to deliver two synergistic therapeutic proteins simultaneously, addressing multiple disease pathways in a single administration. The lead product IKAR-001 (formerly IKC159V) targets geographic atrophy through PEDF neuroprotection and complement modulation. IKAR-002 addresses wet AMD with anti-VEGF and anti-fibrotic mechanisms. IKAR-003 targets intermediate AMD using VectorBuilder's capsid technology for intravitreal delivery. The company also has an undisclosed programme for diabetic macular edema. All products aim to replace frequent eye injections with a single, durable gene therapy treatment.
Differentiator
Problem solved
Functional benefit
Products and services
- IKAR-001 (formerly IKC159V) Bicistronic AAV8-based gene therapy for geographic atrophy (GA), combining pigment epithelium-derived factor (PEDF) for neuroprotection and soluble CD46 (sCD46) for complement modulation. Delivered as a single subretinal injection intended to preserve vision and slow disease progression, targeting the 5M+ GA patient population worldwide with potential extension to 1.5M retinitis pigmentosa patients.
- IKAR-002 (formerly IKC151V)
Quantifiable outcome
- Preclinical studies demonstrate IKAR-001's superiority versus single-pathway complement-only approaches
- +2 more outcomes
Companies that use Ikarovec
Customer profileSegments4 records
Ideal customer profiles2 records
Ikarovec technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Ikarovec partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- VectorBuildercoreIkarovec entered into an exclusive worldwide option agreement with VectorBuilder for their novel AAV capsid technology to be used with IKAR-003 for intermediate AMD. VectorBuilder's proprietary capsid technology enables convenient intravitreal delivery in a doctor's office setting, enhancing patient access. The deal, expected to be finalized, could be valued at over $1 billion. Ikarovec will be responsible for clinical development and commercialization.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Ikarovec competitors and assessment
Company assessmentBroad incumbents
- Apellis Pharmaceuticals: Markets Syfovre, the first FDA-approved therapy for geographic atrophy; directly competes with Ikarovec's lead indication as an established complement-pathway incumbent.
- Iveric Bio (Astellas): Marketer of Izervay (avacincaptad pegol), an FDA-approved complement inhibitor for geographic atrophy; same GA indication as Ikarovec's IKAR-001, but a large incumbent with a broadly diversified ophthalmology portfolio.
- EyeBio (Merck): Ophthalmology biotech co-founded by Ikarovec Chair David Guyer and acquired by Merck in 2024; comparable retinal disease focus and direct management overlap, though now part of Merck's broader portfolio.
Direct peers
- REGENXBIO: AAV gene therapy developer with RGX-314 in pivotal trials for wet AMD using a one-time subretinal/intravitreal approach; highly comparable in modality, indication, and delivery strategy to Ikarovec's IKAR-001/002.
- 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company with ophthalmology programs including 4D-150 for wet AMD; directly comparable therapeutic modality, indication overlap, and clinical-stage positioning.
- Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based therapies for ophthalmic diseases, including wet AMD; directly comparable to Ikarovec as both target major retinal indications with one-time AAV gene therapies.
Emerging players
- Coave Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for ophthalmic and CNS diseases, including retinal degeneration programs; comparable AAV gene therapy modality and ophthalmic focus.
- SpliceBio: Gene therapy company developing dual-AAV therapies for inherited retinal diseases including Stargardt disease; comparable modality (gene therapy for retinal disease) and has direct board linkage via NED Jean-Philippe Combal.
- GenSight Biologics: Clinical-stage gene therapy company with ophthalmology programs (e.g., LUMEVOQ for Leber hereditary optic neuropathy); comparable AAV gene therapy modality targeting vision-threatening eye diseases.
- MeiraGTx Holdings: Clinical-stage gene therapy developer with ophthalmology programs including AAV-CNGB3 and AAV-CNGA3 for retinitis pigmentosa; comparable AAV gene therapy modality targeting inherited retinal diseases with RP indication overlap.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Ikarovec social profiles
Digital presenceIkarovec financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ikarovec leadership team
Management profileNumber of profiles
Profiles9 records
Ikarovec funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ikarovec M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ikarovec
What does Ikarovec do?
Ikarovec is a clinical-stage biotechnology company developing a pipeline of bi-functional (bicistronic) gene therapies that use AAV8 vectors to deliver genetic instructions for two synergistic therapeutic proteins in a single injection. Lead product IKAR-001 targets geographic atrophy via PEDF neuroprotection and sCD46 complement modulation; IKAR-002 addresses wet AMD via anti-VEGF and anti-CTGF; IKAR-003 targets intermediate AMD using VectorBuilder's intravitreal capsid.
Is Ikarovec a public or private company?
Ikarovec is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ikarovec founded?
Ikarovec was founded in 2020. It employs 1 to 10 people.
Where is Ikarovec based?
Ikarovec is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Ikarovec make money?
One revenue line is on record: gene Therapy Product Sales.
Who are Ikarovec's main competitors?
Broad incumbents on record are Apellis Pharmaceuticals, Iveric Bio (Astellas) and EyeBio (Merck). Direct peers are REGENXBIO, 4D Molecular Therapeutics and Adverum Biotechnologies. Emerging players are Coave Therapeutics, SpliceBio, GenSight Biologics and MeiraGTx Holdings.
Does Ikarovec have an API?
No public API is recorded for Ikarovec.
What industry is Ikarovec in?
Ikarovec's product category is Ophthalmic Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.